Medicare Coverage of Anti-Obesity Drugs Begins Next Month Under Temporary Program
Medicare will begin covering weight loss medications starting next month through a program designed as temporary but expected to face political pressure for permanence. The coverage represents a significant policy shift for Medicare, which has historically excluded anti-obesity drugs from its formulary. The program's implementation comes as GLP-1 medications like Wegovy and Zepbound have demonstrated clinical efficacy for weight management but carry substantial cost implications. While positioned as temporary, the coverage expansion may prove difficult to reverse once beneficiaries begin accessing these medications.
While Medicare-specific, this coverage expansion could create precedent and political pressure for similar Medicaid coverage mandates, affecting managed care pharmacy budgets and utilization management strategies for high-cost weight management drugs.
Pharmacy · Managed Care
You might also like